Latest Breaking News On - Alex karlsson parra - Page 1 : comparemela.com

Mendus to present novel data supporting the broad potential of its proprietary cancer vaccine platform at CICON23

Mendus AB , a biopharmaceutical company focused on immunotherapies addressing tumor recurrence, will present novel clinical and preclinical data on the mode of action of its lead clinical program.

United statesCorey davisJorn kaspersHans nijmanAlex karlsson parraHaoxiao zuoMario brkuljErik mantingGerty schreibeltSatwinder kaur singhAmerican society of hematologyLifesci advisorsRadboud institute for molecular life sciencesDepartment of tumor immunologyValency communicationsRadboud university medical centre

Mendus publishes preclinical data demonstrating synergies of ilixadencel and 4-1BB-targeting immunotherapies

Mendus publishes preclinical data demonstrating synergies of ilixadencel and 4-1BB-targeting immunotherapies
finanzen.ch - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanzen.ch Daily Mail and Mail on Sunday newspapers.

Uppsala lanAlex karlsson parraCorey davisErik mantingMario brkuljValency communicationsDepartment of immunologyUppsala universityLifesci advisorsChief scientific officerNasdaq stockholmSci advisors

Mendus appoints NK cell pioneer Lewis Lanier to Scientific Advisory Board

Mendus appoints NK cell pioneer Lewis Lanier to Scientific Advisory Board
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

New yorkUnited statesSan franciscoLewis lanierPawel kalinskiAlex karlsson parraErik mantingAda kruisbeekCorey davisInge marie svaneMario brkuljCancer centerUs national academy of sciencesValency communicationsCancer research instituteUniversity of california

Mendus AB: Mendus Publishes Preclinical Data Demonstrating Significant Anti-Tumor Synergies of Intratumoral Immune Priming with CTLA-4 Inhibition

Intratumoral injection of allogeneic pro-inflammatory dendritic cells ("ilixadencel") substantially and sustainably enhanced an otherwise ineffective systemic anti CTLA-4 treatment in an established in

Julie seidelMario brkuljErik mantingAlex karlsson parraDrug administrationValency communicationsChief scientific officer

Immunicum AB: Immunicum to Present Preclinical Data Demonstrating Synergy of DCP-001 with Standard Treatments for Acute Myeloid Leukemia

COMBINATION OF CANCER RELAPSE VACCINE CANDIDATE WITH 5'-AZACITIDINE AND VENETOCLAX SHOWS SUPERIOR TUMOR REDUCTION IN AN AML MODEL Immunicum AB ("Immunicum" publ; IMMU.ST), a biopharmaceutical

Julie seidelMario brkuljErik mantingAlex karlsson parraSatwinder kaur singhResearch at immunicumValency communicationsAnnual meetingChief scientific officerDirector research